Issue 4/2009
Content (27 Articles)
Gerontology and geriatrics, a worldwide expansion in 2009: Data from the IAGG World Meeting Paris 2009, July 5–9th
B. Vellas, B. Forette
Metabolic response to a ketogenic breakfast in the healthy elderly
E. Freemantle, M. Vandal, J. Tremblay-Mercier, M. Plourde, J. Poirier, S. C. Cunnane
Impact of food aid on food variety and dietary diversity of an elderly community in Sharpeville, South Africa
W. H. Oldewage-Theron, R. Kruger
Unawareness of weight and height - the effect on self-reported prevalence of overweight in a population-based study
E. Ramos, C. Lopes, A. Oliveira, H. Barros
The association of thyroid stimulating hormone levels with cognitive function and depressed mood: The Rancho Bernardo study
D. Kritz-Silverstein, S. T. Schultz, L. A. Palinkas, D. L. Wingard, E. Barrett-Connor
Sleep disorders and their impacts on healthy, dependent, and frail older adults
Valérie Cochen, C. Arbus, M. E. Soto, H. Villars, M. Tiberge, T. Montemayor, C. Hein, M. F. Veccherini, S. -H. Onen, I. Ghorayeb, M. Verny, L. J. Fitten, J. Savage, Y. Dauvilliers, B. Vellas
Biomarkers for Alzheimer’s disease trials — biomarkers for what? A discussion paper
S. Lovestone, M. Thambisetty
Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies?
C. Sampaio
Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment
P. J. Visser
Molecular imaging markers in clinical trials in Alzheimer’s disease
A. Nordberg
Neuro-imaging: Structural and functional imaging
G. B. Frisoni
Structural imaging markers for therapeutic trials in Alzheimer’s disease
N. C. Fox, J. Kennedy
Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data
W. M. Van Der Flier, P. Scheltens
Interest of the new criteria for drug trials in AD
B. Dubois
Use of CSF biomarkers in Alzheimer’s disease clinical trials
K. Blennow, H. Zetterberg
What we have learned from the myriad trials
S. B. Hendrix, G. K. Wilcock
What we have learned from the xaliproden Sanofi-aventis trials
P. Douillet, J. -M. Orgogozo
Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy
C. Wischik, R. Staff
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: The Alzhemedtm (Tramiprosate) experience
D. Saumier, P. S. Aisen, S. Gauthier, B. Vellas, S. H. Ferris, A. Duong, J. Suhy, J. Oh, W. Lau, D. Garceau, D. Haine, J. Sampalis
Enrichment of MCI and early Alzheimer’s disease treatment trials using neurochemical & imaging candidate biomarkers
H. Hampel, K. Broich
The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)
C. C. Gispen-De Wied, M. Kritsidima, A. J. A. Elferink
Frailty: Defining and measuring of a concept
R. E. Pel-Littel, M. J. Schuurmans, M. H. Emmelot-Vonk, H. J. J. Verhaar